aTyr Pharma, Inc. (LIFE) Lowered to “Hold” at Zacks Investment Research
Zacks Investment Research downgraded shares of aTyr Pharma, Inc. (NASDAQ:LIFE) from a buy rating to a hold rating in a report issued on Thursday morning.
According to Zacks, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. “
Several other research analysts also recently weighed in on LIFE. BMO Capital Markets set a $4.00 price target on aTyr Pharma and gave the stock a hold rating in a research note on Tuesday, August 15th. Piper Jaffray Companies began coverage on aTyr Pharma in a research report on Thursday, September 7th. They set an overweight rating and a $7.00 target price for the company. Finally, ValuEngine downgraded aTyr Pharma from a sell rating to a strong sell rating in a research report on Wednesday, September 6th. One research analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company’s stock. The company has a consensus rating of Hold and an average price target of $4.27.
aTyr Pharma (NASDAQ:LIFE) traded up 7.58% on Thursday, hitting $3.55. 107,078 shares of the company’s stock traded hands. The stock has a 50 day moving average price of $3.15 and a 200-day moving average price of $3.42. The stock’s market cap is $84.63 million. aTyr Pharma has a 12 month low of $2.10 and a 12 month high of $4.45.
aTyr Pharma (NASDAQ:LIFE) last posted its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.51) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.57) by $0.06. Equities analysts predict that aTyr Pharma will post ($2.18) earnings per share for the current fiscal year.
In other news, Director Paul Schimmel bought 94,336 shares of the stock in a transaction dated Thursday, August 31st. The stock was purchased at an average cost of $2.65 per share, for a total transaction of $249,990.40. Following the transaction, the director now owns 40,440 shares of the company’s stock, valued at $107,166. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO John Mendlein bought 37,736 shares of the stock in a transaction dated Thursday, August 31st. The shares were purchased at an average price of $2.65 per share, with a total value of $100,000.40. The disclosure for this purchase can be found here. 33.30% of the stock is currently owned by corporate insiders.
An institutional investor recently raised its position in aTyr Pharma stock. EcoR1 Capital LLC grew its position in shares of aTyr Pharma, Inc. (NASDAQ:LIFE) by 134.7% in the first quarter, according to its most recent filing with the SEC. The fund owned 2,292,659 shares of the biotechnology company’s stock after acquiring an additional 1,315,673 shares during the quarter. aTyr Pharma comprises approximately 2.0% of EcoR1 Capital LLC’s holdings, making the stock its 13th largest holding. EcoR1 Capital LLC owned 9.65% of aTyr Pharma worth $8,024,000 at the end of the most recent quarter. Institutional investors own 46.66% of the company’s stock.
aTyr Pharma Company Profile
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Receive News & Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.